The availability of radio-iodinated GRPR/PSMA bispecific heterodimers could provide an advantage for theranostics applications as they could be used for imaging of prostate cancers by SPECT and PET cameras with I-123 and I-124 labels, respectively, and for therapeutic purposes labeled with I-131. This evidence concerns the gene FOLH1 and prostate cancer.